Amgen's Repatha hits wall at SCOTUS but presses ahead—new price breaks included
Jan 09, 2019 - FiercePharma
Amgen has been trying since 2015 to protect its PCSK9 cholesterol drug Repatha by keeping Sanofi and Regeneron's rival Praluent off the market, even going as far as to ask the U.S. Supreme Court to review an ongoing patent fight.
But that attempt fell short this week as SCOTUS refused to hear the company's appeal of a 2017 court decision allowing Sanofi and Regeneron to continue selling its head-to-head rival.
Amgen isn't giving up the fight, though. The company is prepping for a new...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
